Possibilities and risks associated with directly moving from Phase I to Phase III: Adaptive designs and Co

Similar documents
confirmatory clinical trials - The PMDA Perspective -

Accelerating Innovation in Statistical Design

Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials

Overview of requirements for surrogate endpoint adoption by CHMP: a regulatory perspective. Dr Beatriz Flores CDDF- October 2017

SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT -Seamless drug development paradigms

Regulatory Aspects - AML & CLL

A case study design of adaptive dose selection in a combined Phase II/III clinical trial. Junliang Chen, Ph.D November 18, 2016

Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.

Statistics for Clinical Trials: Basics of Phase III Trial Design

Adaptive Treatment Arm Selection in Multivariate Bioequivalence Trials

Statistical Challenges in Immunotherapy: Non Proportional Hazard Model. BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche

Media Release. FDA grants Priority Review for Roche s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer

Accelerating Phase II-III Oncology Drug Development Through the Use of Adaptive Designs

Accelerated approval of Perjeta for neoadjuvant use also converted to full approval

Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference

Third Quarter 2015 Earnings Call. November 9, 2015

Choice of appropriate endpoints in clinical trials. Fortunato Ciardiello Second University of Naples

Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations

The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?

NASH Regulatory Landscape. Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH

(Regulatory) views on Biomarker defined Subgroups

Interim Futility Monitoring When Assessing Immune Therapies With A Potentially Delayed Treatment Effect

Utilizing Seamless Adaptive Designs and Considering Multiplicity Adjustment for NASH Clinical Trials

Synopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02

Selection and estimation in exploratory subgroup analyses a proposal

Rare Disease Workshop 5: Post Marketing Confirmatory Studies in Rare Diseases

Panitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd

PATIENTS REPORTED OUTCOMES IN ONCOLOGY PATIENT- CENTERED DRUG DEVELOPMENT: OPPORTUNITIES & CHALLENGES

TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer

Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights

EMEA experience with endpoints for Oncology drug approval

Benefit - Risk Analysis for Oncology Clinical Trials

Building a Premier Oncology Biotech

Improving outcomes as rapidly as possible for patients. Multi-arm, multi stage platform, umbrella and basket protocols

Technology appraisal guidance Published: 23 February 2011 nice.org.uk/guidance/ta214

Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell

How to improve the reliability of Single Arm Trials

FDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.

Stopping a cancer trial early: is it really for the benefit of patients? What about the quality of data?

Design considerations for Phase II trials incorporating biomarkers

SURROGATE ENDPOINTS IN ONCOLOGY: OBJECTIVES, METHODOLOGICAL OVERVIEW, AND CURRENT STATUS

What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012

Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable

Framework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

TRUST Trial on Radical Upfront Surgical Therapy

Group Sequential Design: Uses and Abuses

Designing Clinical Trials

Cabozantinib (Cometriq )

Is there a Cookbook for Oncology Clinical Trials?

Reflection paper on assessment of cardiovascular safety profile of medicinal products

Study Design and Analysis in Late-Stage Cancer Immunotherapy Trials

Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies

Roche leads the clinical development of risdiplam as part of a collaboration with the SMA Foundation and PTC Therapeutics.

Noninferiority Clinical Trials

Building a Premier Oncology Biotech

September 30, Eric BASTINGS, MD. Acting Director Division of Neurology Products (DNP) Center for Drug Evaluation and Research (CDER)

Safeguarding public health CHMP's view on multiplicity; through assessment, advice and guidelines

Basket Trials: Features, Examples, and Challenges

Evaluating Adaptive Dose Finding Designs and Methods

XII Michelangelo Foundation Seminar

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We

Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs

Innovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

Discussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK

Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials

Practical Statistical Reasoning in Clinical Trials

Statistical Challenges for Novel Technologies. Roseann M. White, MA Director of Pragmatic Clinical Trial Statistics Duke Clinical Research Institute

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY

BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY

CHMP Type II variation assessment report

Model-Based Drug Development. Russell Reeve, Innovation, Quintiles May 22, 2012 Society of Clinical Trials

Bayesian Joint Modelling of Benefit and Risk in Drug Development

Building a Premier Oncology Biotech

95% 2.5% 2.5% +2SD 95% of data will 95% be within of data will 1.96 be within standard deviations 1.96 of sample mean

Summary. Table 1 Blinatumomab administration, as per European marketing authorisation

What are the regulatory issues. prevention trials?

Neoadjuvant therapy a new pathway to registration?

midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age.

Roche s GAZYVARO approved in Switzerland for people with previously untreated follicular lymphoma which are in need of systemic treatment

The Roles of Short Term Endpoints in. Clinical Trial Planning and Design

PTAC meeting held on 5 & 6 May (minutes for web publishing)

Media Release. Basel, 6 th February 2018

An introduction to Quality by Design. Dr Martin Landray University of Oxford


PCI Biotech press release 24 th August Attachment

To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York

Review. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials

Pascal Soriot, Head of Strategic Marketing

Policy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015

Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial

BENDAMUSTINE + RITUXIMAB IN CLL

Technology appraisal guidance Published: 24 November 2010 nice.org.uk/guidance/ta208

Clinical Trial Design to Expedite Drug Development Mary W. Redman, Ph.D.

Statistical aspects of surgery in clinical trials. Laurence Collette, PhD Statistics Department, EORTC, Brussels (BE)

that the best available evidence has not demonstrated that pcr can predict long-term outcomes in the neoadjuvant setting.

E11(R1) Addendum to E11: Clinical Investigation of Medicinal Products in the Pediatric Population Step4

Rolling Dose Studies

Panel Two: Evidence for Use of Maintenance Therapy

On the Utility of Subgroup Analyses in Confirmatory Clinical Trials

Transcription:

Possibilities and risks associated with directly moving from Phase I to Phase III: Adaptive designs and Co Dominik Heinzmann, PhD Global Development Team Leader Breast/Gyn Cancer Associate Director Biostatistics, Roche, Basel CDDF workshop on Innovative Clinical Trials 12/13-June-2017, Frankfurt, Germany

Table of Contents Case example 1: Multiple doses seamless adaptive Phase II/III Case examples 2: Phase I data on intermediate endpoints Case examples 3: Sample size adjustment at interim

Case example: Kadcyla (trastuzumabemtasine, T-DM1) Phase I data: A wealth of data of Kadcyla from breast cancer and other solid tumors A lot of data from Herceptin in gastric No Phase I data specifically collected for Kadcyla in gastric cancer Challenges: Observed a lower exposure of monoclonal antibodies in gastric cancer patients as compared to other solid tumors Solution : Adaptive seamless design with dose selection

Adaptive Designs: EMA CHMP Reflection paper: Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design (Oct 2007) A study design is called adaptive if statistical methodology allows the modification of a design element (e.g. sample size, randomization ratio, number of treatment arms) at an interim analysis with full control of the type 1 error.

Traditional Development and Seamless Adaptive Phase II/III Drop a dose Stage 1 Stage 2

GATSBY Study Design Pros Savings in time and cost (including no white space between Phase 2 and 3) Full Type I error control of study design and statistical procedure Ability to use/contribute stage 1 patients for confirmatory portion of study Dose selection performed by idmc with Sponsor remaining fully blinded Potential to implement futility interim analysis Cons Operational more challenging and complex compared to separate Phase II followed by Phase III development Non-selected group to continue with the pre-planned treatment Complex simulations needed to understand design operating characteristics including type I error, power and any bias in estimates idmc dose selection as somewhat «black box» outside of Sponsor control Potentially more upfront resources needed

Table of Contents Case example 1: Multiple doses seamless adaptive Phase II/III Case examples 2: Phase I data on intermediate endpoints Case examples 3: Sample size adjustment at interim

Case example: Drug in AML Phase I data: Motivating complete response rate for AML CR allows in about 40-50% a transplant (~ cure ) Challenges: Even improved CR rates would still be low (10-20%), hence remaining uncertainty if this drives an OS benefit Solution : Phase III design with interim analysis for futility based on intermediate clinical endpoints

Mechanistic model for AML: Link CR with long-term efficacy (3-component cure rate model) H 0 Responder s Short-term Long-term H 1 Nonresponders Nonresponders Responder s OS per patient Short-term Long-term

Interim analysis Option 1: CR / EFS: + Get quicker interim decision - Interim based on surrogate endpoint association between CR to OS unclear. EFS additional mitigates this uncertainty. Option 2: OS as interim endpoint + Directly accounts for safety aspect of early deaths + Entire setup much simpler: less assumptions need to be made. - Timelines much longer, in particualr if median OS >> median EFS.

Assessment EFS Futility #Pts at interim Model Gate 1.1 Gate 1.0 Gate 0.9 100 H0 36% 51% 66% 100 H1 6% 10% 19% 120 H0 34% 50% 67% 120 H1 5% 8% 14% 140 H0 32% 49% 68% 140 H1 3% 6% 12% - P(correctly stopping under H0) - P(wrong stopping under H1) Disclaimer: Data generated from real example by superimposing noise

Table of Contents Case example 1: Multiple doses seamless adaptive Phase II/III Case examples 2: Phase I data on intermediate endpoints Case examples 3: Sample size adjustment at interim

AML: VALOR trial Zoran Antonijevic, JSM 2015 Vosaroxin & cytarabine vs Placebo & cytarabine Existing (limited) data: Single arm small Phase II Assume 5/7 month median for Control/Treatment (HR=0.71) Require 375 events in 450 subjects (19 month duration) But estimate of median is subject to uncertainty What if 5/6.5 month median on Control/Treatment (HR=0.77)? HR=0.77 is still clinically meaningful More events needed, larger sample size Solution : Adaptive design with sample size adjustment at interim

Design elements idmc decisions (guidance based on conditional power at interim with 187 events (50% information fraction)) Continue the trial to 375 events in 450 patients Adjust sample size to 562 events in 675 patients Stop early for overwhelming efficacy or futility

Decision at interim based on conditional power Conditional power: Probability of success (statistical significance) at the end of the trial given the current data trend at the interim analysis

Results Results interim analysis Interim was conducted at 173 events, rather than 187 as planned HR was 0.76 Conditional Power was 82%, in the promising zone, so sample size was increased as pre-specified Results final analysis Unstratified results: HR = 0.87 (95% CI 0.73-1.02), p=0.061 Stratified results: HR = 0.83, p=0.024 Medians: 7.5 months on Vos vs. 6.1 months on Placebo

Conclusions We have reviewed three potential cases to deal with limited information based on early phase data Suggests that there is not one-fits-all approach, but that approach need to be tailored This implies it takes some time to work up the scenarios and thus such approach shall be considered early in development to allow sufficient time to develop approach

Doing now what patients need next